Haptoglobin: Basic and clinical aspects

Antioxidants and Redox Signaling

Volumn 12, Issue 2, 2010, Pages 293-304

  Levy, Andrew P ^a   Asleh, Rabea ^a   Blum, Shany ^a   Levy, Nina S ^a   Miller Lotan, Rachel ^a   Kalet Litman, Shiri ^a   Anbinder, Yefim ^a   Lache, Orit ^a   Nakhoul, Farid M ^a   Asaf, Roy ^a   Farbstein, Dan ^a   Pollak, Mordechai ^a   Soloveichik, Yitzhak Z ^a   Strauss, Merav ^a   Alshiek, Jonia ^a   Livshits, Alina ^a   Schwartz, Avery ^a   Awad, Hoda ^a   Jad, Kheir ^a   Goldenstein, Hagit ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANT; CYTOKINE; HAPTOGLOBIN; HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN;

ALLELE; ANGIOGENESIS; CARDIOVASCULAR DISEASE; COMPLEX FORMATION; DIABETES MELLITUS; DNA POLYMORPHISM; ERYTHROCYTE; GENE LOCUS; GENE STRUCTURE; GENOTYPE; HEMOLYSIS; HUMAN; INFECTION; KIDNEY DISEASE; NEOPLASM; NONHUMAN; PHARMACOGENOMICS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; SUBARACHNOID HEMORRHAGE; ANIMAL; GENETIC PREDISPOSITION; GENETICS; METABOLISM; OXIDATIVE STRESS; PHYSIOLOGY; VASCULAR DISEASE;

ANIMALS; ANTIOXIDANTS; DIABETES MELLITUS; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HAPTOGLOBINS; HEMOGLOBINS; HUMANS; OXIDATIVE STRESS; VASCULAR DISEASES;

EID: 77949521505     PISSN: 15230864     EISSN: None     Source Type: Journal    
DOI: 10.1089/ars.2009.2793     Document Type: Review

References (62)

1. Allison AC and Rees W. The binding of hemoglobin by plasma proteins. Brit Med J 2: 1137-1143, 1957.
2. Asleh R, Marsh S, Shiltruck M, Binah O, Guetta J, Lejbkowicz F, Enav B, Shehadeh N, Kanter Y, Lache O, Cohen O, Levy NS, and Levy AP. Genetically determined heterogeneity in hemoglobin scavenging and susceptibility to diabetic cardiovascular disease. Circ Res 92: 1193-1200, 2003. (Pubitemid 36723646)
3. Asleh R, Guetta J, Kalet-Litman S, Miller-Lotan R, and Levy AP. Haptoglobin genotype and diabetes dependent differences in iron mediated oxidative stress in vitro and in vivo. Circ Res 96: 435-441, 2005. (Pubitemid 40354537)
4. Asleh R, Miller-Lotan R, Aviram M, Hayek T, Yulish M, Levy JE, Miller B, Blum S, Milman U, Shapira C, and Levy AP. Haptoglobin genotype is a regulator of reverse cholesterol transport in diabetes in vitro and in vivo. Circ Res 99: 1419-1425, 2006. (Pubitemid 44949678)
5. Asleh R, Blum S, Kalet-Litman S, Alsheik J, Miller-Lotan R, Asaf R, Rock W, Aviram M, Milman U, Shapira C, Abassi Z, and Levy AP. Correction of HDL dysfunction in individuals with diabetes and the haptoglobin 2-2 genotype. Diabetes 57: 2794-2800, 2008.
6. Atkinson SH, Rockett K, Sirugo G, Bejon PA, Fulford A, O'Connell MA, Bailey R, Kwaitkowski DP, and Prentice AM. Seasonal childhood anemia in West Africa is associated with the haptoglobin 2-2 genotype. PLoS Med 3: e172, 2006.
7. Azarov I, He, X, Jeffers A, Ucer B, Hantgan RR, Levy AP, and Kim-Shapiro DB. Rate of nitric oxide scavenging by hemoglobin bound to haptoglobin. Nitric Oxide Biol Chem 18: 296-302, 2008.
8. Blum S, Milman U, Shapira C, and Levy AP. Pharmacoge-nomic application of the haptoglobin genotype in the prevention of diabetic cardiovascular disease. Pharmacogenomics 9: 989-991, 2008.
9. Borsody M, Burke A, Coplin W, Miller-Lotan R, and Levy AP. Haptoglobin and the development of cerebral artery vasospasm after subarachnoid hemorrhage. Neurology 66: 634-640, 2006. (Pubitemid 43739814)
10. Boyle JJ, Harrington HA, Piper E, Elderfield K, Stark J, Landis RC, and Haskard DO. Coronary intraplaque hemorrhage evokes a novel atheroprotective macrophage phe-notype. Am J Path 174: 1097-1108, 2009.
11. Buehler PW, Abraham B, Vallelian F, Linnemayr C, Pereira CP, Cipollo JF, Jia Y, Mikolajczyk M, Boretti FS, Schoedon G, Alayash AI, and Schaer DJ. Haptoglobin preserves the CD163 hemoglobin scavenger pathway by shielding hemoglobin from peroxidative modification. Blood 113: 2578-2586, 2009.
12. Buehler PW, Vallelian F, Mikolajczyk M, Schoedon G, Schweizer T, Alayash AI, and Schaer DJ. Structural stabilization in tetrameric or polymeric hemoglobin determines its interaction with endogenous antioxidant scavenger pathways. Antioxid Redox Signal 10: 1449-1462, 2008.
13. Bunn HF and Jandl JH. Exchange of heme among hemoglobin molecules. Proc Natl Acad Sci USA 56: 974-978, 1966.
14. Chaichana K, Levy AP, Miller-Lotan R, Shakur S, and Ta-margo RJ. Haptoglobin 2-2 genotype determines chronic vasospasm after experimental subarachnoid hemorrhage. Stroke 38: 3266-3271, 2007. (Pubitemid 350175747)
15. Cid MC, Grant DS, Hoffman GS, Auerbach R, Fauci AS, and Kleinman HK. Identification of haptoglobin as an angiogenic factor in sera from patients with systemic vasculitis. J Clin Invest 91: 977-985, 1993. (Pubitemid 23095272)
16. Costacou T, Ferrell RE, and Orchard TJ. Haptoglobin genotype: A determinant of cardiovascular complication risk in type I diabetes. Diabetes 57: 1702-1706, 2008.
17. DeBacquer D, DeBacker G, Langlois M, Delanghe J, Keste-loot H, and Kornitzer M. Haptoglobin polymorphism as a risk factor for coronary heart disease mortality. Atherosclerosis 157: 161-166, 2001. (Pubitemid 32539366)
18. Delanghe J, Langlois M, Duprez D, De Buyzere M, and Clement D. Haptoglobin polymorphism and peripheral arterial occlusive disease. Atherosclerosis 145: 287-292, 1999. (Pubitemid 29359136)
19. Fagoonee S, Gburek J, Hirsch E, Marro S, Moestrup SK, Laurberg JM, Christensen EI-Silengo L, Altruda F, Tolosano E. Plasma protein haptoglobin modulates renal iron loading. Am J Path 166: 973-983, 2005. (Pubitemid 40524423)
20. Frank M, Lache O, Enav B, Szafranek T, Levy NS, Ricklis RM, and Levy AP. Structure=function analysis of the anti-oxidant properties of haptoglobin. Blood 98: 3693-3698, 2001.
21. Freeman T. Haptoglobin metabolism in relation to red cell destruction. Proc XII Colloq Prot Biol Fluid Bruges, p 344, 1964.
22. Gburek J, Verroust PJ, Willnow TE, Fyfe JC, Nowacki W, Jacobsen C, Moestrup SK, and Christiansen EI. Megalin and cubulin are endocytic receptors involved in renal clearance of hemoglobin. J Am Soc Nephrol 13: 423-430, 2002. (Pubitemid 34110430)
23. Graversen JH, Madsen M, and Moestrup SK. CD163: A signal receptor scavenging haptoglobin-hemoglobin complexes from plasma. Int J Biochem Cell Biol 34: 309-314, 2002. (Pubitemid 34164272)
24. Guetta J, Strauss M, Levy NS, Fahoum L, and Levy AP. Haptoglobin genotype modulates the balance of Th1=Th2 cytokines produced by macrophages exposed to free hemoglobin. Atherosclerosis 91: 48-53, 2007. (Pubitemid 46227428)
25. Jayle MF and Moretti J. Haptoglobin: Biochemical, genetic and physiopathologic aspects. Prog Hem 3: 342-359, 1962.
26. Keene WR and Jandl JH. The sites of hemoglobin catabolism. Blood 26: 705-719, 1965.
27. Koch W, Latz W, Eichinger M, Roguin A, Levy AP, Schomig A, and Kastrati A. Genotyping of the common haptoglobin Hp 1/2 polymorphism based on PCR. Clin Chem 48: 1377-1382, 2002. (Pubitemid 34925770)
28. Lai IH, Lin KY, Larsson M, Yang MC, Shiau CH, Liao MH, and Mao SJ. A unique tetrameric structure of deer plasma haptoglobin-an evolutionary advantage in the Hp 2-2 phe-notype withhomogenousstructure. FEBS J 275: 981-983, 2008.
29. Langlois MR and Delanghe JR. Biological and clinical significance of haptoglobin polymorphism in humans. Clin Chem 42: 1589-1600, 1996. (Pubitemid 26354735)
30. Laurell CB and Nyman M. Studies on the serum haptoglobin level in hemoglobinemia and its influence on renal excretion of hemoglobin. Blood 12: 493-506, 1957.
31. Levy AP, Hochberg I, Jablonski K, Resnick H, Best L, Lee ET, and Howard BV. Haptoglobin phenotype and the risk of cardiovascular disease in individuals with diabetes: The Strong Heart Study. J Am Coll Card 40: 1984-1990, 2002. (Pubitemid 35425366)
32. Levy AP, Gerstein H, Lotan R, Ratner R, McQueen M, Lonn E, and Pogue J. The effect of vitamin E supplementation on cardiovascular risk in diabetic individuals with different haptoglobin phenotypes. Diabetes Care 27: 2767, 2004. (Pubitemid 39441487)
33. Levy AP, Levy JE, Kalet-Litman S, Miller-Lotan R, Levy NS, Asaf R, Guetta J, Yang C, Purushothaman KR, Fuster V, and Moreno PR. Haptoglobin genotype is a determinant of iron, lipid peroxidation and macrophage accumulation in the atherosclerotic plaque. Arteriosclerosis Thromb Vasc Biol 27: 134-140, 2007. (Pubitemid 46360390)
34. Levy AP, Purosothaman KR, Levy NS, Purosothaman M, Strauss M, Asleh R, Marsh S, Cohen O, Moestrup SK, Moller HJ, Zias EA, Benhayon D, Fuster V, and Moreno PR. Downregulation of the hemoglobin scavenger receptor in individuals with diabetes and the Hp 2-2 genotype: Implications for the response to intraplaque hemorrhage and plaque vulnerability. Circ Res 101: 106-110, 2007. (Pubitemid 47094629)
35. Lim SK, Kim H, Lim SK, bin Ali A, Lim YK, Wang Y, Chong SM, Costantini F, and Baumman H. Increased susceptibility in Hp knockout mice during acute hemolysis. Blood 92: 1870-1877, 1998. (Pubitemid 28446675)
36. Lohr NL, Warltier DC, Chilian WM, and Weihrauch D. Haptoglobin expression and activity during coronary col-lateralization. Am J Physiol Heart Circ Physiol 288: H1389- 1395, 2005. (Pubitemid 40270049)
37. Maeda N, Yang F, Barnett DR, Bowman BH, and Smithies O. Duplication within the haptoglobin hp 2 gene. Nature 309: 131-135, 1984.
38. Miller ER, Barriuso RP, Dalal D, Riemersma RA, Appel LJ, and Guallar E: Meta-analysis: High dosage vitamin E supplementation may increase all cause mortality. Ann Intern Med 142: 37-46, 2005.
39. Milman U, Blum S, Shapira C, Aronson D, Miller-Lotan R, Anbinder Y, Alsheik J, Bennett L, Kostenko M, Landau M, Keidar S, Levy Y, Khemlin A, Radan A, and Levy AP. Vitamin E supplementation reduces cardiovascular events in a subgroup of middle-aged individuals with both Type 2 diabetes mellitus and the haptoglobin 2-2 genotype: A prospective, double-blinded clinical trial. Art Thromb Vasc Biol 28: 341-347, 2008. (Pubitemid 351161209)
40. Miyoshi E and Nakano M. Fucosylated Haptoglobin is a novel marker for pancreatic cancer: detailed analyses of oligo-saccharide structures. Proteomics 8:3257-3262, 2008.
41. Moreno PR, Purushothaman KR, Purushothaman M, Muntner P, Levy NS, Fuster V, Fallon JT, Lento P, Winter-stern A, and Levy AP. Haptoglobin genotype is a major determinant of the amount of iron in the human atherosclerotic plaque. J Am Coll Card 52: 1049-1051, 2008.
42. Nagel RL and Gibson QH. The binding of hemoglobin to haptoglobin and its relation to subunit dissociation of hemoglobin. J Biol Chem 246: 69-73, 1971.
43. Nakhoul FM, Miller-Lotan R, Awaad H, Asleh R, and Levy AP. Hypothesis: Haptoglobin genotype and diabetic ne-phropathy. Nature Clin Pract Neph 3: 339-344, 2007. (Pubitemid 46834869)
44. Peacock AC, Pastewka JV, Reed RA, and Ness AT. Haptoglobin-hemoglobin interaction. Stoichiometry. Biochemistry 9: 2275-2279, 1970.
45. Polonovski M and Jayle MF. Existence dans le plasma sanguine d'une substance activant l'action peroxdasique de l'hemoglobine. C. r. Soc. Biol 129: 457, 1938.
46. Polonovski M and Jayle MF. Sur la preparation d'une nou-velle fraction des proteins plasmatiques, l'haptoglobine. C. r. Acad. Sci. 211: 517, 1940.
47. Roguin A, Koch W, Kastrati A, Aronson D, Schomig A, and Levy AP. Haptoglobin genotype is predictive of major adverse cardiac events in the one year period after PTCA in individuals with diabetes. Diabetes Care 26: 2628-2631, 2003. (Pubitemid 37052111)
48. Schaer CA, Schoedon G, Imhof A, Kurrer MO, and Schaer DJ. Constitutive endocytosis of CD163 mediates hemoglobin-heme uptake and determines the noninflammatory and protective transcriptional response of macrophages to hemoglobin. Circ Res 99: 943-950, 2006. (Pubitemid 44657797)
49. Smithies O. Zone electrophoresis in starch gels: Group variation in the serum proteins of normal human adults. Bio-chem J 61: 629-641, 1955.
50. Smithies O and Walker NR. Notation for serum protein groups and the genes controlling their inheritance. Nature 178: 694-695, 1956.
51. Spagnuolo MS, Cigliano L, D'Andrea LD, Pedone C, and Abrescia P. Assignment of the binding site for haptoglobin on apolipoprotien A-1. J Biol Chem 280: 1193-1198, 2005.
52. Strauss M and Levy AP. Regulation of CD163 associated casein kinase activity is haptoglobin genotype dependent. Mol Cell Biochem 317: 131-135, 2008.
53. Suleiman M, Aronson D, Asleh R, Kapelovich MR, Roguin A, Meisel SR, Shochat M, Suleiman A, Reisner SA, Markie-wicz W, Hammerman H, Lotan R, Levy NS, and Levy AP. Haptoglobin polymorphism predicts 30-day mortality and heart failure in patients with diabetes and acute myocardial infarction. Diabetes 54: 2802-2806, 2005. (Pubitemid 41233605)
54. The Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Vitamin E supplementation and cardiovascular events in high risk patients. N Engl J Med 342: 154-160, 2000.
55. Tolosano E, Fagoonee S, Hirsch E, Berger FG, Baumann H, Silengo L, and Altruda F. Enhanced splenomegaly and severe liver inflammation in haptoglobin=hemopexin double null mice after acute hemolysis. Blood 100: 4201-4208, 2002. (Pubitemid 35402055)
56. Veneziale CM, McGuckin WF, Hermans PE, and Mankin HT. Hypohaptoglobinemia and valvular heart disease: Association with hemolysis after insertion of valvular prosthesis and in cases in which operation had not been performed. Mayo Clin Proc 41: 657-662, 1966.
57. Victor J, Cheong W, Chen JJS, Levy N, Miller-Lotan R, Levy AP, Blum S, Orchard T, Evans R, and Costacou T. Clinical results of a rapid screening assay for haptoglobin 2-2: A cardiovascular disease risk marker in diabetes. Diabetes 58 (suppl 1): 652-P, 2009.
58. Wang Y, Kinzie E, Berger FG, Lim SK, and Baumann H. Haptoglobin, an inflammation inducible plasma protein. Redox Rep 6: 379-385, 2001. (Pubitemid 34134332)
59. Watanabe J, Chou KJ, Liao JC, Miao Y, Meng HH, Ge H, Grijalva V, Hama S, Kozak K, Buga G, Whitelegge JP, Lee TD, Farias-Eisner R, Navab M, Fogelman AM, and Reddy ST. Differential association of hemoglobin with proin-flammatory high density lipoproteins in atherogenic= hyperlipidemic mice. A novel biomarker of atherosclerosis. J Biol Chem 282: 23698-23707, 2007. (Pubitemid 47311940)
60. Watanabe J, Grijalva V, Hama S, Barbour K, Berger F, Navab M, Fogelman AM, and Reddy ST. Hemoglobin and its scavenger protein haptoglobin associate with apoA-1 containing particles and influence the inflammatory properties and function of high density lipoprotein. J Biol Chem 284: 18292-18301, 2009.
61. Wasserzug O, Blum S, Klement E, Miller-Lotan R, and Levy AP. Haptoglobin 1-1 genotype and the risk of life-threatening streptococcus infection: Evolutionary implications. J Infect 54: 410, 2007. (Pubitemid 46430268)
62. Wejman JC, Hovsepian D, Wall JS, Hainfeld JF, and Greer J. Structure and assembly of haptoglobin polymers by electron microscopy. J Mol Biol 174: 343-368, 1984. (Pubitemid 15011744)